X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2022
Details:
Deal combines HemoShear’s REVEAL-Tx™ platform with Takeda’s drug discovery and development capabilities. REVEAL-Tx™ allows drug candidates to be studied at human concentrations and provides valuable insights into complex pathophysiological pathways.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $470.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2021
Details:
REVEAL-Tx™ provides pathways by replicating human disease with great accuracy. HemoShear’s human disease models, in combination with its advanced proprietary computational biology tools, identify novel treatment approaches and reduce risk of failure.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 16, 2021
Details:
Under the terms of the agreement Horizon received exclusive access to HemoShear's proprietary disease modeling REVEAL-TxTM drug discovery platform to discover new therapeutics for gout.
Lead Product(s): Undisclosed
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2021
Details:
The Series A funding will enable the company to complete a phase 2 study of its lead compound, HST5040, for the treatment of methylmalonic acidemia (MMA) and propionic acidemia (PA), as well as fund future clinical studies and earlier stage programs.
Lead Product(s): HST5040
Therapeutic Area: Genetic Disease Product Name: HST5040
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Suvretta Capital
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 10, 2021
Details:
HST5040 is an investigational oral small molecule therapy developed by HemoShear to address metabolic abnormalities associated with MMA and PA.
Lead Product(s): HST5040
Therapeutic Area: Genetic Disease Product Name: HST5040
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda’s discovery portfolio.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $470.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2020
Details:
REVEAL-Tx™ combines physiological and computational models of disease to identify novel treatment approaches and select drug candidates in a human-relevant disease context.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
Details:
HemoShear received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration for HST5040, a once-daily oral small molecule drug being developed to treat methylmalonic acidemia (MMA) and propionic acidemia (PA).
Lead Product(s): HST5040
Therapeutic Area: Genetic Disease Product Name: HST5040
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
The U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a phase 2 clinical trial of HST5040, an oral small molecule drug for the treatment of patients with methylmalonic acidemia (MMA) and propionic acidemia (PA).
Lead Product(s): HST5040
Therapeutic Area: Genetic Disease Product Name: HST5040
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
